Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/malaria-drug-made-in-india-14741/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/malaria-drug-made-in-india-14741/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/malaria-drug-made-in-india-14741/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/malaria-drug-made-in-india-14741/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f23bfc0c638-trace').style.display = (document.getElementById('cakeErr67f23bfc0c638-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f23bfc0c638-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f23bfc0c638-code').style.display = (document.getElementById('cakeErr67f23bfc0c638-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f23bfc0c638-context').style.display = (document.getElementById('cakeErr67f23bfc0c638-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f23bfc0c638-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f23bfc0c638-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 14617,
		&#039;title&#039; =&gt; &#039;Malaria drug, made in India&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world&#039;s latest drug against malaria, an alternative to standard anti-malarial therapy.&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s Ranbaxy Laboratories today launched the new drug for the treatment of uncomplicated malaria caused by the Plasmodium falciparum parasite, after nine years of research which was partly supported by the Indian government.&lt;br /&gt;
&lt;br /&gt;
Clinical trials in India, Tanzania, and Thailand have suggested that the drug yields a cure rate of over 95 per cent and could serve as an alternative to existing anti-malarial therapy based on the compound called artemisinin derived from plants. Senior Ranbaxy officials announced today that the drug would be made available in India at Rs 130 for three tablets, and treatment would involve taking a single tablet for three days.&lt;br /&gt;
&lt;br /&gt;
The drug is a combination of two molecules &amp;mdash; arterolane, discovered and patented several years ago by Professor Jonathan Vennestrom, a medicinal chemistry expert at the University of Nebraska Medical Centre in the US &amp;mdash; and piperaquine, an anti-malarial known since the 1960s.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;Arterolane is a short-acting anti-malarial molecule and piperaquine is a long-acting molecule. We&amp;rsquo;ve combined the two to create a new combination therapy exactly on lines recommended by the World Health Organisation,&amp;quot; said Sudershan Arora, head of research at Ranbaxy.&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s department of science and technology (DST) contributed about Rs 5 crore to the research that involved, among other objectives, changing the salt structure of arterolane. &amp;ldquo;We changed it from a tosylate salt to a maleate salt, increasing its solubility and thus its availability in the body,&amp;rdquo; Arora said.&lt;br /&gt;
&lt;br /&gt;
Public health specialists estimate that about half of India&amp;rsquo;s estimated 1.5 million cases of malaria each year are caused by the Plasmodium falciparum parasite, the others are caused by Plasmodium vivax .&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;This new drug is intended for the treatment of uncomplicated falciparum malaria &amp;mdash; not for severe malaria (also known as malignant malaria) which requires different treatment strategies,&amp;rdquo; said Neena Valecha, a senior scientist at the National Institute of Malaria Research, New Delhi, who was involved in assessing the clinical trials of the drug in India.&lt;br /&gt;
&lt;br /&gt;
Malaria patients who also have severe anaemia or severe jaundice or have developed cerebral malaria are not classified as having uncomplicated malaria, Valecha said.&amp;ldquo;Early treatment reduces the risk of complicated malaria.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
The number of deaths caused by malaria in India remains in dispute with some researchers challenging the government&amp;rsquo;s claim that about 1000 people die from malaria each year. The Union health minister Ghulam Nabi Azad, who was the chief guest at today&amp;rsquo;s launch, said the Indian Council of Medical Research is assessing a revised estimate of about 35,000 deaths per year made by a panel of experts set up by the health ministry.&lt;br /&gt;
&lt;br /&gt;
The standard therapy for uncomplicated falciparum malaria involves artemisinin-based drugs which are substances derived from plants whose availability hinges on crop output. However, arterolane production can be scaled up whenever required because of its synthetic origin.&lt;br /&gt;
&lt;br /&gt;
Ranbaxy began to pursue research on arterolane jointly with the international agency Medicines for Malaria Venture in 2003, and continued to pursue its development even after MMV withdrew financial support in early 2007. The company then turned to the DST for the series of crucial clinical trials that led to approval by drug regulators.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;We&amp;rsquo;re hoping that the government considers this drug for inclusion into the national malaria treatment programme,&amp;rdquo; Arun Sawhney, the chief executive officer of Ranbaxy, told reporters at the launch today.&lt;br /&gt;
&lt;br /&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 26 April, 2012, http://www.telegraphindia.com/1120426/jsp/nation/story_15420477.jsp#.T5jZtVL5nYQ&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;malaria-drug-made-in-india-14741&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 14741,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 14617,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Malaria drug, made in India&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;malaria,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Telegraph

An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world&#039;s latest drug against malaria, an alternative to standard anti-malarial therapy.

India&amp;rsquo;s Ranbaxy Laboratories today launched the new drug for...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world&#039;s latest drug against malaria, an alternative to standard anti-malarial therapy.&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s Ranbaxy Laboratories today launched the new drug for the treatment of uncomplicated malaria caused by the Plasmodium falciparum parasite, after nine years of research which was partly supported by the Indian government.&lt;br /&gt;&lt;br /&gt;Clinical trials in India, Tanzania, and Thailand have suggested that the drug yields a cure rate of over 95 per cent and could serve as an alternative to existing anti-malarial therapy based on the compound called artemisinin derived from plants. Senior Ranbaxy officials announced today that the drug would be made available in India at Rs 130 for three tablets, and treatment would involve taking a single tablet for three days.&lt;br /&gt;&lt;br /&gt;The drug is a combination of two molecules &amp;mdash; arterolane, discovered and patented several years ago by Professor Jonathan Vennestrom, a medicinal chemistry expert at the University of Nebraska Medical Centre in the US &amp;mdash; and piperaquine, an anti-malarial known since the 1960s.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;Arterolane is a short-acting anti-malarial molecule and piperaquine is a long-acting molecule. We&amp;rsquo;ve combined the two to create a new combination therapy exactly on lines recommended by the World Health Organisation,&amp;quot; said Sudershan Arora, head of research at Ranbaxy.&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s department of science and technology (DST) contributed about Rs 5 crore to the research that involved, among other objectives, changing the salt structure of arterolane. &amp;ldquo;We changed it from a tosylate salt to a maleate salt, increasing its solubility and thus its availability in the body,&amp;rdquo; Arora said.&lt;br /&gt;&lt;br /&gt;Public health specialists estimate that about half of India&amp;rsquo;s estimated 1.5 million cases of malaria each year are caused by the Plasmodium falciparum parasite, the others are caused by Plasmodium vivax .&lt;br /&gt;&lt;br /&gt;&amp;ldquo;This new drug is intended for the treatment of uncomplicated falciparum malaria &amp;mdash; not for severe malaria (also known as malignant malaria) which requires different treatment strategies,&amp;rdquo; said Neena Valecha, a senior scientist at the National Institute of Malaria Research, New Delhi, who was involved in assessing the clinical trials of the drug in India.&lt;br /&gt;&lt;br /&gt;Malaria patients who also have severe anaemia or severe jaundice or have developed cerebral malaria are not classified as having uncomplicated malaria, Valecha said.&amp;ldquo;Early treatment reduces the risk of complicated malaria.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;The number of deaths caused by malaria in India remains in dispute with some researchers challenging the government&amp;rsquo;s claim that about 1000 people die from malaria each year. The Union health minister Ghulam Nabi Azad, who was the chief guest at today&amp;rsquo;s launch, said the Indian Council of Medical Research is assessing a revised estimate of about 35,000 deaths per year made by a panel of experts set up by the health ministry.&lt;br /&gt;&lt;br /&gt;The standard therapy for uncomplicated falciparum malaria involves artemisinin-based drugs which are substances derived from plants whose availability hinges on crop output. However, arterolane production can be scaled up whenever required because of its synthetic origin.&lt;br /&gt;&lt;br /&gt;Ranbaxy began to pursue research on arterolane jointly with the international agency Medicines for Malaria Venture in 2003, and continued to pursue its development even after MMV withdrew financial support in early 2007. The company then turned to the DST for the series of crucial clinical trials that led to approval by drug regulators.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;We&amp;rsquo;re hoping that the government considers this drug for inclusion into the national malaria treatment programme,&amp;rdquo; Arun Sawhney, the chief executive officer of Ranbaxy, told reporters at the launch today.&lt;br /&gt;&lt;br /&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 14617,
	&#039;title&#039; =&gt; &#039;Malaria drug, made in India&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world&#039;s latest drug against malaria, an alternative to standard anti-malarial therapy.&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s Ranbaxy Laboratories today launched the new drug for the treatment of uncomplicated malaria caused by the Plasmodium falciparum parasite, after nine years of research which was partly supported by the Indian government.&lt;br /&gt;
&lt;br /&gt;
Clinical trials in India, Tanzania, and Thailand have suggested that the drug yields a cure rate of over 95 per cent and could serve as an alternative to existing anti-malarial therapy based on the compound called artemisinin derived from plants. Senior Ranbaxy officials announced today that the drug would be made available in India at Rs 130 for three tablets, and treatment would involve taking a single tablet for three days.&lt;br /&gt;
&lt;br /&gt;
The drug is a combination of two molecules &amp;mdash; arterolane, discovered and patented several years ago by Professor Jonathan Vennestrom, a medicinal chemistry expert at the University of Nebraska Medical Centre in the US &amp;mdash; and piperaquine, an anti-malarial known since the 1960s.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;Arterolane is a short-acting anti-malarial molecule and piperaquine is a long-acting molecule. We&amp;rsquo;ve combined the two to create a new combination therapy exactly on lines recommended by the World Health Organisation,&amp;quot; said Sudershan Arora, head of research at Ranbaxy.&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s department of science and technology (DST) contributed about Rs 5 crore to the research that involved, among other objectives, changing the salt structure of arterolane. &amp;ldquo;We changed it from a tosylate salt to a maleate salt, increasing its solubility and thus its availability in the body,&amp;rdquo; Arora said.&lt;br /&gt;
&lt;br /&gt;
Public health specialists estimate that about half of India&amp;rsquo;s estimated 1.5 million cases of malaria each year are caused by the Plasmodium falciparum parasite, the others are caused by Plasmodium vivax .&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;This new drug is intended for the treatment of uncomplicated falciparum malaria &amp;mdash; not for severe malaria (also known as malignant malaria) which requires different treatment strategies,&amp;rdquo; said Neena Valecha, a senior scientist at the National Institute of Malaria Research, New Delhi, who was involved in assessing the clinical trials of the drug in India.&lt;br /&gt;
&lt;br /&gt;
Malaria patients who also have severe anaemia or severe jaundice or have developed cerebral malaria are not classified as having uncomplicated malaria, Valecha said.&amp;ldquo;Early treatment reduces the risk of complicated malaria.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
The number of deaths caused by malaria in India remains in dispute with some researchers challenging the government&amp;rsquo;s claim that about 1000 people die from malaria each year. The Union health minister Ghulam Nabi Azad, who was the chief guest at today&amp;rsquo;s launch, said the Indian Council of Medical Research is assessing a revised estimate of about 35,000 deaths per year made by a panel of experts set up by the health ministry.&lt;br /&gt;
&lt;br /&gt;
The standard therapy for uncomplicated falciparum malaria involves artemisinin-based drugs which are substances derived from plants whose availability hinges on crop output. However, arterolane production can be scaled up whenever required because of its synthetic origin.&lt;br /&gt;
&lt;br /&gt;
Ranbaxy began to pursue research on arterolane jointly with the international agency Medicines for Malaria Venture in 2003, and continued to pursue its development even after MMV withdrew financial support in early 2007. The company then turned to the DST for the series of crucial clinical trials that led to approval by drug regulators.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;We&amp;rsquo;re hoping that the government considers this drug for inclusion into the national malaria treatment programme,&amp;rdquo; Arun Sawhney, the chief executive officer of Ranbaxy, told reporters at the launch today.&lt;br /&gt;
&lt;br /&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 26 April, 2012, http://www.telegraphindia.com/1120426/jsp/nation/story_15420477.jsp#.T5jZtVL5nYQ&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;malaria-drug-made-in-india-14741&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 14741,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 14617
$metaTitle = &#039;LATEST NEWS UPDATES | Malaria drug, made in India&#039;
$metaKeywords = &#039;malaria,Health&#039;
$metaDesc = &#039;
-The Telegraph

An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world&#039;s latest drug against malaria, an alternative to standard anti-malarial therapy.

India&amp;rsquo;s Ranbaxy Laboratories today launched the new drug for...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world&#039;s latest drug against malaria, an alternative to standard anti-malarial therapy.&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s Ranbaxy Laboratories today launched the new drug for the treatment of uncomplicated malaria caused by the Plasmodium falciparum parasite, after nine years of research which was partly supported by the Indian government.&lt;br /&gt;&lt;br /&gt;Clinical trials in India, Tanzania, and Thailand have suggested that the drug yields a cure rate of over 95 per cent and could serve as an alternative to existing anti-malarial therapy based on the compound called artemisinin derived from plants. Senior Ranbaxy officials announced today that the drug would be made available in India at Rs 130 for three tablets, and treatment would involve taking a single tablet for three days.&lt;br /&gt;&lt;br /&gt;The drug is a combination of two molecules &amp;mdash; arterolane, discovered and patented several years ago by Professor Jonathan Vennestrom, a medicinal chemistry expert at the University of Nebraska Medical Centre in the US &amp;mdash; and piperaquine, an anti-malarial known since the 1960s.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;Arterolane is a short-acting anti-malarial molecule and piperaquine is a long-acting molecule. We&amp;rsquo;ve combined the two to create a new combination therapy exactly on lines recommended by the World Health Organisation,&amp;quot; said Sudershan Arora, head of research at Ranbaxy.&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s department of science and technology (DST) contributed about Rs 5 crore to the research that involved, among other objectives, changing the salt structure of arterolane. &amp;ldquo;We changed it from a tosylate salt to a maleate salt, increasing its solubility and thus its availability in the body,&amp;rdquo; Arora said.&lt;br /&gt;&lt;br /&gt;Public health specialists estimate that about half of India&amp;rsquo;s estimated 1.5 million cases of malaria each year are caused by the Plasmodium falciparum parasite, the others are caused by Plasmodium vivax .&lt;br /&gt;&lt;br /&gt;&amp;ldquo;This new drug is intended for the treatment of uncomplicated falciparum malaria &amp;mdash; not for severe malaria (also known as malignant malaria) which requires different treatment strategies,&amp;rdquo; said Neena Valecha, a senior scientist at the National Institute of Malaria Research, New Delhi, who was involved in assessing the clinical trials of the drug in India.&lt;br /&gt;&lt;br /&gt;Malaria patients who also have severe anaemia or severe jaundice or have developed cerebral malaria are not classified as having uncomplicated malaria, Valecha said.&amp;ldquo;Early treatment reduces the risk of complicated malaria.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;The number of deaths caused by malaria in India remains in dispute with some researchers challenging the government&amp;rsquo;s claim that about 1000 people die from malaria each year. The Union health minister Ghulam Nabi Azad, who was the chief guest at today&amp;rsquo;s launch, said the Indian Council of Medical Research is assessing a revised estimate of about 35,000 deaths per year made by a panel of experts set up by the health ministry.&lt;br /&gt;&lt;br /&gt;The standard therapy for uncomplicated falciparum malaria involves artemisinin-based drugs which are substances derived from plants whose availability hinges on crop output. However, arterolane production can be scaled up whenever required because of its synthetic origin.&lt;br /&gt;&lt;br /&gt;Ranbaxy began to pursue research on arterolane jointly with the international agency Medicines for Malaria Venture in 2003, and continued to pursue its development even after MMV withdrew financial support in early 2007. The company then turned to the DST for the series of crucial clinical trials that led to approval by drug regulators.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;We&amp;rsquo;re hoping that the government considers this drug for inclusion into the national malaria treatment programme,&amp;rdquo; Arun Sawhney, the chief executive officer of Ranbaxy, told reporters at the launch today.&lt;br /&gt;&lt;br /&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/malaria-drug-made-in-india-14741.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Malaria drug, made in India | Im4change.org</title>
    <meta name="description" content="
-The Telegraph

An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world's latest drug against malaria, an alternative to standard anti-malarial therapy.

India&rsquo;s Ranbaxy Laboratories today launched the new drug for..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Malaria drug, made in India</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Telegraph<br /><br />An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world's latest drug against malaria, an alternative to standard anti-malarial therapy.<br /><br />India&rsquo;s Ranbaxy Laboratories today launched the new drug for the treatment of uncomplicated malaria caused by the Plasmodium falciparum parasite, after nine years of research which was partly supported by the Indian government.<br /><br />Clinical trials in India, Tanzania, and Thailand have suggested that the drug yields a cure rate of over 95 per cent and could serve as an alternative to existing anti-malarial therapy based on the compound called artemisinin derived from plants. Senior Ranbaxy officials announced today that the drug would be made available in India at Rs 130 for three tablets, and treatment would involve taking a single tablet for three days.<br /><br />The drug is a combination of two molecules &mdash; arterolane, discovered and patented several years ago by Professor Jonathan Vennestrom, a medicinal chemistry expert at the University of Nebraska Medical Centre in the US &mdash; and piperaquine, an anti-malarial known since the 1960s.<br /><br />&ldquo;Arterolane is a short-acting anti-malarial molecule and piperaquine is a long-acting molecule. We&rsquo;ve combined the two to create a new combination therapy exactly on lines recommended by the World Health Organisation,&quot; said Sudershan Arora, head of research at Ranbaxy.<br /><br />India&rsquo;s department of science and technology (DST) contributed about Rs 5 crore to the research that involved, among other objectives, changing the salt structure of arterolane. &ldquo;We changed it from a tosylate salt to a maleate salt, increasing its solubility and thus its availability in the body,&rdquo; Arora said.<br /><br />Public health specialists estimate that about half of India&rsquo;s estimated 1.5 million cases of malaria each year are caused by the Plasmodium falciparum parasite, the others are caused by Plasmodium vivax .<br /><br />&ldquo;This new drug is intended for the treatment of uncomplicated falciparum malaria &mdash; not for severe malaria (also known as malignant malaria) which requires different treatment strategies,&rdquo; said Neena Valecha, a senior scientist at the National Institute of Malaria Research, New Delhi, who was involved in assessing the clinical trials of the drug in India.<br /><br />Malaria patients who also have severe anaemia or severe jaundice or have developed cerebral malaria are not classified as having uncomplicated malaria, Valecha said.&ldquo;Early treatment reduces the risk of complicated malaria.&rdquo;<br /><br />The number of deaths caused by malaria in India remains in dispute with some researchers challenging the government&rsquo;s claim that about 1000 people die from malaria each year. The Union health minister Ghulam Nabi Azad, who was the chief guest at today&rsquo;s launch, said the Indian Council of Medical Research is assessing a revised estimate of about 35,000 deaths per year made by a panel of experts set up by the health ministry.<br /><br />The standard therapy for uncomplicated falciparum malaria involves artemisinin-based drugs which are substances derived from plants whose availability hinges on crop output. However, arterolane production can be scaled up whenever required because of its synthetic origin.<br /><br />Ranbaxy began to pursue research on arterolane jointly with the international agency Medicines for Malaria Venture in 2003, and continued to pursue its development even after MMV withdrew financial support in early 2007. The company then turned to the DST for the series of crucial clinical trials that led to approval by drug regulators.<br /><br />&ldquo;We&rsquo;re hoping that the government considers this drug for inclusion into the national malaria treatment programme,&rdquo; Arun Sawhney, the chief executive officer of Ranbaxy, told reporters at the launch today.<br /><br /></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f23bfc0c638-trace').style.display = (document.getElementById('cakeErr67f23bfc0c638-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f23bfc0c638-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f23bfc0c638-code').style.display = (document.getElementById('cakeErr67f23bfc0c638-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f23bfc0c638-context').style.display = (document.getElementById('cakeErr67f23bfc0c638-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f23bfc0c638-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f23bfc0c638-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 14617,
		&#039;title&#039; =&gt; &#039;Malaria drug, made in India&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world&#039;s latest drug against malaria, an alternative to standard anti-malarial therapy.&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s Ranbaxy Laboratories today launched the new drug for the treatment of uncomplicated malaria caused by the Plasmodium falciparum parasite, after nine years of research which was partly supported by the Indian government.&lt;br /&gt;
&lt;br /&gt;
Clinical trials in India, Tanzania, and Thailand have suggested that the drug yields a cure rate of over 95 per cent and could serve as an alternative to existing anti-malarial therapy based on the compound called artemisinin derived from plants. Senior Ranbaxy officials announced today that the drug would be made available in India at Rs 130 for three tablets, and treatment would involve taking a single tablet for three days.&lt;br /&gt;
&lt;br /&gt;
The drug is a combination of two molecules &amp;mdash; arterolane, discovered and patented several years ago by Professor Jonathan Vennestrom, a medicinal chemistry expert at the University of Nebraska Medical Centre in the US &amp;mdash; and piperaquine, an anti-malarial known since the 1960s.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;Arterolane is a short-acting anti-malarial molecule and piperaquine is a long-acting molecule. We&amp;rsquo;ve combined the two to create a new combination therapy exactly on lines recommended by the World Health Organisation,&amp;quot; said Sudershan Arora, head of research at Ranbaxy.&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s department of science and technology (DST) contributed about Rs 5 crore to the research that involved, among other objectives, changing the salt structure of arterolane. &amp;ldquo;We changed it from a tosylate salt to a maleate salt, increasing its solubility and thus its availability in the body,&amp;rdquo; Arora said.&lt;br /&gt;
&lt;br /&gt;
Public health specialists estimate that about half of India&amp;rsquo;s estimated 1.5 million cases of malaria each year are caused by the Plasmodium falciparum parasite, the others are caused by Plasmodium vivax .&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;This new drug is intended for the treatment of uncomplicated falciparum malaria &amp;mdash; not for severe malaria (also known as malignant malaria) which requires different treatment strategies,&amp;rdquo; said Neena Valecha, a senior scientist at the National Institute of Malaria Research, New Delhi, who was involved in assessing the clinical trials of the drug in India.&lt;br /&gt;
&lt;br /&gt;
Malaria patients who also have severe anaemia or severe jaundice or have developed cerebral malaria are not classified as having uncomplicated malaria, Valecha said.&amp;ldquo;Early treatment reduces the risk of complicated malaria.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
The number of deaths caused by malaria in India remains in dispute with some researchers challenging the government&amp;rsquo;s claim that about 1000 people die from malaria each year. The Union health minister Ghulam Nabi Azad, who was the chief guest at today&amp;rsquo;s launch, said the Indian Council of Medical Research is assessing a revised estimate of about 35,000 deaths per year made by a panel of experts set up by the health ministry.&lt;br /&gt;
&lt;br /&gt;
The standard therapy for uncomplicated falciparum malaria involves artemisinin-based drugs which are substances derived from plants whose availability hinges on crop output. However, arterolane production can be scaled up whenever required because of its synthetic origin.&lt;br /&gt;
&lt;br /&gt;
Ranbaxy began to pursue research on arterolane jointly with the international agency Medicines for Malaria Venture in 2003, and continued to pursue its development even after MMV withdrew financial support in early 2007. The company then turned to the DST for the series of crucial clinical trials that led to approval by drug regulators.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;We&amp;rsquo;re hoping that the government considers this drug for inclusion into the national malaria treatment programme,&amp;rdquo; Arun Sawhney, the chief executive officer of Ranbaxy, told reporters at the launch today.&lt;br /&gt;
&lt;br /&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 26 April, 2012, http://www.telegraphindia.com/1120426/jsp/nation/story_15420477.jsp#.T5jZtVL5nYQ&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;malaria-drug-made-in-india-14741&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 14741,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 14617,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Malaria drug, made in India&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;malaria,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Telegraph

An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world&#039;s latest drug against malaria, an alternative to standard anti-malarial therapy.

India&amp;rsquo;s Ranbaxy Laboratories today launched the new drug for...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world&#039;s latest drug against malaria, an alternative to standard anti-malarial therapy.&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s Ranbaxy Laboratories today launched the new drug for the treatment of uncomplicated malaria caused by the Plasmodium falciparum parasite, after nine years of research which was partly supported by the Indian government.&lt;br /&gt;&lt;br /&gt;Clinical trials in India, Tanzania, and Thailand have suggested that the drug yields a cure rate of over 95 per cent and could serve as an alternative to existing anti-malarial therapy based on the compound called artemisinin derived from plants. Senior Ranbaxy officials announced today that the drug would be made available in India at Rs 130 for three tablets, and treatment would involve taking a single tablet for three days.&lt;br /&gt;&lt;br /&gt;The drug is a combination of two molecules &amp;mdash; arterolane, discovered and patented several years ago by Professor Jonathan Vennestrom, a medicinal chemistry expert at the University of Nebraska Medical Centre in the US &amp;mdash; and piperaquine, an anti-malarial known since the 1960s.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;Arterolane is a short-acting anti-malarial molecule and piperaquine is a long-acting molecule. We&amp;rsquo;ve combined the two to create a new combination therapy exactly on lines recommended by the World Health Organisation,&amp;quot; said Sudershan Arora, head of research at Ranbaxy.&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s department of science and technology (DST) contributed about Rs 5 crore to the research that involved, among other objectives, changing the salt structure of arterolane. &amp;ldquo;We changed it from a tosylate salt to a maleate salt, increasing its solubility and thus its availability in the body,&amp;rdquo; Arora said.&lt;br /&gt;&lt;br /&gt;Public health specialists estimate that about half of India&amp;rsquo;s estimated 1.5 million cases of malaria each year are caused by the Plasmodium falciparum parasite, the others are caused by Plasmodium vivax .&lt;br /&gt;&lt;br /&gt;&amp;ldquo;This new drug is intended for the treatment of uncomplicated falciparum malaria &amp;mdash; not for severe malaria (also known as malignant malaria) which requires different treatment strategies,&amp;rdquo; said Neena Valecha, a senior scientist at the National Institute of Malaria Research, New Delhi, who was involved in assessing the clinical trials of the drug in India.&lt;br /&gt;&lt;br /&gt;Malaria patients who also have severe anaemia or severe jaundice or have developed cerebral malaria are not classified as having uncomplicated malaria, Valecha said.&amp;ldquo;Early treatment reduces the risk of complicated malaria.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;The number of deaths caused by malaria in India remains in dispute with some researchers challenging the government&amp;rsquo;s claim that about 1000 people die from malaria each year. The Union health minister Ghulam Nabi Azad, who was the chief guest at today&amp;rsquo;s launch, said the Indian Council of Medical Research is assessing a revised estimate of about 35,000 deaths per year made by a panel of experts set up by the health ministry.&lt;br /&gt;&lt;br /&gt;The standard therapy for uncomplicated falciparum malaria involves artemisinin-based drugs which are substances derived from plants whose availability hinges on crop output. However, arterolane production can be scaled up whenever required because of its synthetic origin.&lt;br /&gt;&lt;br /&gt;Ranbaxy began to pursue research on arterolane jointly with the international agency Medicines for Malaria Venture in 2003, and continued to pursue its development even after MMV withdrew financial support in early 2007. The company then turned to the DST for the series of crucial clinical trials that led to approval by drug regulators.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;We&amp;rsquo;re hoping that the government considers this drug for inclusion into the national malaria treatment programme,&amp;rdquo; Arun Sawhney, the chief executive officer of Ranbaxy, told reporters at the launch today.&lt;br /&gt;&lt;br /&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 14617,
	&#039;title&#039; =&gt; &#039;Malaria drug, made in India&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world&#039;s latest drug against malaria, an alternative to standard anti-malarial therapy.&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s Ranbaxy Laboratories today launched the new drug for the treatment of uncomplicated malaria caused by the Plasmodium falciparum parasite, after nine years of research which was partly supported by the Indian government.&lt;br /&gt;
&lt;br /&gt;
Clinical trials in India, Tanzania, and Thailand have suggested that the drug yields a cure rate of over 95 per cent and could serve as an alternative to existing anti-malarial therapy based on the compound called artemisinin derived from plants. Senior Ranbaxy officials announced today that the drug would be made available in India at Rs 130 for three tablets, and treatment would involve taking a single tablet for three days.&lt;br /&gt;
&lt;br /&gt;
The drug is a combination of two molecules &amp;mdash; arterolane, discovered and patented several years ago by Professor Jonathan Vennestrom, a medicinal chemistry expert at the University of Nebraska Medical Centre in the US &amp;mdash; and piperaquine, an anti-malarial known since the 1960s.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;Arterolane is a short-acting anti-malarial molecule and piperaquine is a long-acting molecule. We&amp;rsquo;ve combined the two to create a new combination therapy exactly on lines recommended by the World Health Organisation,&amp;quot; said Sudershan Arora, head of research at Ranbaxy.&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s department of science and technology (DST) contributed about Rs 5 crore to the research that involved, among other objectives, changing the salt structure of arterolane. &amp;ldquo;We changed it from a tosylate salt to a maleate salt, increasing its solubility and thus its availability in the body,&amp;rdquo; Arora said.&lt;br /&gt;
&lt;br /&gt;
Public health specialists estimate that about half of India&amp;rsquo;s estimated 1.5 million cases of malaria each year are caused by the Plasmodium falciparum parasite, the others are caused by Plasmodium vivax .&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;This new drug is intended for the treatment of uncomplicated falciparum malaria &amp;mdash; not for severe malaria (also known as malignant malaria) which requires different treatment strategies,&amp;rdquo; said Neena Valecha, a senior scientist at the National Institute of Malaria Research, New Delhi, who was involved in assessing the clinical trials of the drug in India.&lt;br /&gt;
&lt;br /&gt;
Malaria patients who also have severe anaemia or severe jaundice or have developed cerebral malaria are not classified as having uncomplicated malaria, Valecha said.&amp;ldquo;Early treatment reduces the risk of complicated malaria.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
The number of deaths caused by malaria in India remains in dispute with some researchers challenging the government&amp;rsquo;s claim that about 1000 people die from malaria each year. The Union health minister Ghulam Nabi Azad, who was the chief guest at today&amp;rsquo;s launch, said the Indian Council of Medical Research is assessing a revised estimate of about 35,000 deaths per year made by a panel of experts set up by the health ministry.&lt;br /&gt;
&lt;br /&gt;
The standard therapy for uncomplicated falciparum malaria involves artemisinin-based drugs which are substances derived from plants whose availability hinges on crop output. However, arterolane production can be scaled up whenever required because of its synthetic origin.&lt;br /&gt;
&lt;br /&gt;
Ranbaxy began to pursue research on arterolane jointly with the international agency Medicines for Malaria Venture in 2003, and continued to pursue its development even after MMV withdrew financial support in early 2007. The company then turned to the DST for the series of crucial clinical trials that led to approval by drug regulators.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;We&amp;rsquo;re hoping that the government considers this drug for inclusion into the national malaria treatment programme,&amp;rdquo; Arun Sawhney, the chief executive officer of Ranbaxy, told reporters at the launch today.&lt;br /&gt;
&lt;br /&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 26 April, 2012, http://www.telegraphindia.com/1120426/jsp/nation/story_15420477.jsp#.T5jZtVL5nYQ&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;malaria-drug-made-in-india-14741&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 14741,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 14617
$metaTitle = &#039;LATEST NEWS UPDATES | Malaria drug, made in India&#039;
$metaKeywords = &#039;malaria,Health&#039;
$metaDesc = &#039;
-The Telegraph

An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world&#039;s latest drug against malaria, an alternative to standard anti-malarial therapy.

India&amp;rsquo;s Ranbaxy Laboratories today launched the new drug for...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world&#039;s latest drug against malaria, an alternative to standard anti-malarial therapy.&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s Ranbaxy Laboratories today launched the new drug for the treatment of uncomplicated malaria caused by the Plasmodium falciparum parasite, after nine years of research which was partly supported by the Indian government.&lt;br /&gt;&lt;br /&gt;Clinical trials in India, Tanzania, and Thailand have suggested that the drug yields a cure rate of over 95 per cent and could serve as an alternative to existing anti-malarial therapy based on the compound called artemisinin derived from plants. Senior Ranbaxy officials announced today that the drug would be made available in India at Rs 130 for three tablets, and treatment would involve taking a single tablet for three days.&lt;br /&gt;&lt;br /&gt;The drug is a combination of two molecules &amp;mdash; arterolane, discovered and patented several years ago by Professor Jonathan Vennestrom, a medicinal chemistry expert at the University of Nebraska Medical Centre in the US &amp;mdash; and piperaquine, an anti-malarial known since the 1960s.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;Arterolane is a short-acting anti-malarial molecule and piperaquine is a long-acting molecule. We&amp;rsquo;ve combined the two to create a new combination therapy exactly on lines recommended by the World Health Organisation,&amp;quot; said Sudershan Arora, head of research at Ranbaxy.&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s department of science and technology (DST) contributed about Rs 5 crore to the research that involved, among other objectives, changing the salt structure of arterolane. &amp;ldquo;We changed it from a tosylate salt to a maleate salt, increasing its solubility and thus its availability in the body,&amp;rdquo; Arora said.&lt;br /&gt;&lt;br /&gt;Public health specialists estimate that about half of India&amp;rsquo;s estimated 1.5 million cases of malaria each year are caused by the Plasmodium falciparum parasite, the others are caused by Plasmodium vivax .&lt;br /&gt;&lt;br /&gt;&amp;ldquo;This new drug is intended for the treatment of uncomplicated falciparum malaria &amp;mdash; not for severe malaria (also known as malignant malaria) which requires different treatment strategies,&amp;rdquo; said Neena Valecha, a senior scientist at the National Institute of Malaria Research, New Delhi, who was involved in assessing the clinical trials of the drug in India.&lt;br /&gt;&lt;br /&gt;Malaria patients who also have severe anaemia or severe jaundice or have developed cerebral malaria are not classified as having uncomplicated malaria, Valecha said.&amp;ldquo;Early treatment reduces the risk of complicated malaria.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;The number of deaths caused by malaria in India remains in dispute with some researchers challenging the government&amp;rsquo;s claim that about 1000 people die from malaria each year. The Union health minister Ghulam Nabi Azad, who was the chief guest at today&amp;rsquo;s launch, said the Indian Council of Medical Research is assessing a revised estimate of about 35,000 deaths per year made by a panel of experts set up by the health ministry.&lt;br /&gt;&lt;br /&gt;The standard therapy for uncomplicated falciparum malaria involves artemisinin-based drugs which are substances derived from plants whose availability hinges on crop output. However, arterolane production can be scaled up whenever required because of its synthetic origin.&lt;br /&gt;&lt;br /&gt;Ranbaxy began to pursue research on arterolane jointly with the international agency Medicines for Malaria Venture in 2003, and continued to pursue its development even after MMV withdrew financial support in early 2007. The company then turned to the DST for the series of crucial clinical trials that led to approval by drug regulators.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;We&amp;rsquo;re hoping that the government considers this drug for inclusion into the national malaria treatment programme,&amp;rdquo; Arun Sawhney, the chief executive officer of Ranbaxy, told reporters at the launch today.&lt;br /&gt;&lt;br /&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/malaria-drug-made-in-india-14741.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Malaria drug, made in India | Im4change.org</title>
    <meta name="description" content="
-The Telegraph

An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world's latest drug against malaria, an alternative to standard anti-malarial therapy.

India&rsquo;s Ranbaxy Laboratories today launched the new drug for..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Malaria drug, made in India</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Telegraph<br /><br />An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world's latest drug against malaria, an alternative to standard anti-malarial therapy.<br /><br />India&rsquo;s Ranbaxy Laboratories today launched the new drug for the treatment of uncomplicated malaria caused by the Plasmodium falciparum parasite, after nine years of research which was partly supported by the Indian government.<br /><br />Clinical trials in India, Tanzania, and Thailand have suggested that the drug yields a cure rate of over 95 per cent and could serve as an alternative to existing anti-malarial therapy based on the compound called artemisinin derived from plants. Senior Ranbaxy officials announced today that the drug would be made available in India at Rs 130 for three tablets, and treatment would involve taking a single tablet for three days.<br /><br />The drug is a combination of two molecules &mdash; arterolane, discovered and patented several years ago by Professor Jonathan Vennestrom, a medicinal chemistry expert at the University of Nebraska Medical Centre in the US &mdash; and piperaquine, an anti-malarial known since the 1960s.<br /><br />&ldquo;Arterolane is a short-acting anti-malarial molecule and piperaquine is a long-acting molecule. We&rsquo;ve combined the two to create a new combination therapy exactly on lines recommended by the World Health Organisation,&quot; said Sudershan Arora, head of research at Ranbaxy.<br /><br />India&rsquo;s department of science and technology (DST) contributed about Rs 5 crore to the research that involved, among other objectives, changing the salt structure of arterolane. &ldquo;We changed it from a tosylate salt to a maleate salt, increasing its solubility and thus its availability in the body,&rdquo; Arora said.<br /><br />Public health specialists estimate that about half of India&rsquo;s estimated 1.5 million cases of malaria each year are caused by the Plasmodium falciparum parasite, the others are caused by Plasmodium vivax .<br /><br />&ldquo;This new drug is intended for the treatment of uncomplicated falciparum malaria &mdash; not for severe malaria (also known as malignant malaria) which requires different treatment strategies,&rdquo; said Neena Valecha, a senior scientist at the National Institute of Malaria Research, New Delhi, who was involved in assessing the clinical trials of the drug in India.<br /><br />Malaria patients who also have severe anaemia or severe jaundice or have developed cerebral malaria are not classified as having uncomplicated malaria, Valecha said.&ldquo;Early treatment reduces the risk of complicated malaria.&rdquo;<br /><br />The number of deaths caused by malaria in India remains in dispute with some researchers challenging the government&rsquo;s claim that about 1000 people die from malaria each year. The Union health minister Ghulam Nabi Azad, who was the chief guest at today&rsquo;s launch, said the Indian Council of Medical Research is assessing a revised estimate of about 35,000 deaths per year made by a panel of experts set up by the health ministry.<br /><br />The standard therapy for uncomplicated falciparum malaria involves artemisinin-based drugs which are substances derived from plants whose availability hinges on crop output. However, arterolane production can be scaled up whenever required because of its synthetic origin.<br /><br />Ranbaxy began to pursue research on arterolane jointly with the international agency Medicines for Malaria Venture in 2003, and continued to pursue its development even after MMV withdrew financial support in early 2007. The company then turned to the DST for the series of crucial clinical trials that led to approval by drug regulators.<br /><br />&ldquo;We&rsquo;re hoping that the government considers this drug for inclusion into the national malaria treatment programme,&rdquo; Arun Sawhney, the chief executive officer of Ranbaxy, told reporters at the launch today.<br /><br /></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f23bfc0c638-trace').style.display = (document.getElementById('cakeErr67f23bfc0c638-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f23bfc0c638-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f23bfc0c638-code').style.display = (document.getElementById('cakeErr67f23bfc0c638-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f23bfc0c638-context').style.display = (document.getElementById('cakeErr67f23bfc0c638-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f23bfc0c638-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f23bfc0c638-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 14617,
		&#039;title&#039; =&gt; &#039;Malaria drug, made in India&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world&#039;s latest drug against malaria, an alternative to standard anti-malarial therapy.&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s Ranbaxy Laboratories today launched the new drug for the treatment of uncomplicated malaria caused by the Plasmodium falciparum parasite, after nine years of research which was partly supported by the Indian government.&lt;br /&gt;
&lt;br /&gt;
Clinical trials in India, Tanzania, and Thailand have suggested that the drug yields a cure rate of over 95 per cent and could serve as an alternative to existing anti-malarial therapy based on the compound called artemisinin derived from plants. Senior Ranbaxy officials announced today that the drug would be made available in India at Rs 130 for three tablets, and treatment would involve taking a single tablet for three days.&lt;br /&gt;
&lt;br /&gt;
The drug is a combination of two molecules &amp;mdash; arterolane, discovered and patented several years ago by Professor Jonathan Vennestrom, a medicinal chemistry expert at the University of Nebraska Medical Centre in the US &amp;mdash; and piperaquine, an anti-malarial known since the 1960s.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;Arterolane is a short-acting anti-malarial molecule and piperaquine is a long-acting molecule. We&amp;rsquo;ve combined the two to create a new combination therapy exactly on lines recommended by the World Health Organisation,&amp;quot; said Sudershan Arora, head of research at Ranbaxy.&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s department of science and technology (DST) contributed about Rs 5 crore to the research that involved, among other objectives, changing the salt structure of arterolane. &amp;ldquo;We changed it from a tosylate salt to a maleate salt, increasing its solubility and thus its availability in the body,&amp;rdquo; Arora said.&lt;br /&gt;
&lt;br /&gt;
Public health specialists estimate that about half of India&amp;rsquo;s estimated 1.5 million cases of malaria each year are caused by the Plasmodium falciparum parasite, the others are caused by Plasmodium vivax .&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;This new drug is intended for the treatment of uncomplicated falciparum malaria &amp;mdash; not for severe malaria (also known as malignant malaria) which requires different treatment strategies,&amp;rdquo; said Neena Valecha, a senior scientist at the National Institute of Malaria Research, New Delhi, who was involved in assessing the clinical trials of the drug in India.&lt;br /&gt;
&lt;br /&gt;
Malaria patients who also have severe anaemia or severe jaundice or have developed cerebral malaria are not classified as having uncomplicated malaria, Valecha said.&amp;ldquo;Early treatment reduces the risk of complicated malaria.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
The number of deaths caused by malaria in India remains in dispute with some researchers challenging the government&amp;rsquo;s claim that about 1000 people die from malaria each year. The Union health minister Ghulam Nabi Azad, who was the chief guest at today&amp;rsquo;s launch, said the Indian Council of Medical Research is assessing a revised estimate of about 35,000 deaths per year made by a panel of experts set up by the health ministry.&lt;br /&gt;
&lt;br /&gt;
The standard therapy for uncomplicated falciparum malaria involves artemisinin-based drugs which are substances derived from plants whose availability hinges on crop output. However, arterolane production can be scaled up whenever required because of its synthetic origin.&lt;br /&gt;
&lt;br /&gt;
Ranbaxy began to pursue research on arterolane jointly with the international agency Medicines for Malaria Venture in 2003, and continued to pursue its development even after MMV withdrew financial support in early 2007. The company then turned to the DST for the series of crucial clinical trials that led to approval by drug regulators.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;We&amp;rsquo;re hoping that the government considers this drug for inclusion into the national malaria treatment programme,&amp;rdquo; Arun Sawhney, the chief executive officer of Ranbaxy, told reporters at the launch today.&lt;br /&gt;
&lt;br /&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 26 April, 2012, http://www.telegraphindia.com/1120426/jsp/nation/story_15420477.jsp#.T5jZtVL5nYQ&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;malaria-drug-made-in-india-14741&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 14741,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 14617,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Malaria drug, made in India&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;malaria,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Telegraph

An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world&#039;s latest drug against malaria, an alternative to standard anti-malarial therapy.

India&amp;rsquo;s Ranbaxy Laboratories today launched the new drug for...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world&#039;s latest drug against malaria, an alternative to standard anti-malarial therapy.&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s Ranbaxy Laboratories today launched the new drug for the treatment of uncomplicated malaria caused by the Plasmodium falciparum parasite, after nine years of research which was partly supported by the Indian government.&lt;br /&gt;&lt;br /&gt;Clinical trials in India, Tanzania, and Thailand have suggested that the drug yields a cure rate of over 95 per cent and could serve as an alternative to existing anti-malarial therapy based on the compound called artemisinin derived from plants. Senior Ranbaxy officials announced today that the drug would be made available in India at Rs 130 for three tablets, and treatment would involve taking a single tablet for three days.&lt;br /&gt;&lt;br /&gt;The drug is a combination of two molecules &amp;mdash; arterolane, discovered and patented several years ago by Professor Jonathan Vennestrom, a medicinal chemistry expert at the University of Nebraska Medical Centre in the US &amp;mdash; and piperaquine, an anti-malarial known since the 1960s.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;Arterolane is a short-acting anti-malarial molecule and piperaquine is a long-acting molecule. We&amp;rsquo;ve combined the two to create a new combination therapy exactly on lines recommended by the World Health Organisation,&amp;quot; said Sudershan Arora, head of research at Ranbaxy.&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s department of science and technology (DST) contributed about Rs 5 crore to the research that involved, among other objectives, changing the salt structure of arterolane. &amp;ldquo;We changed it from a tosylate salt to a maleate salt, increasing its solubility and thus its availability in the body,&amp;rdquo; Arora said.&lt;br /&gt;&lt;br /&gt;Public health specialists estimate that about half of India&amp;rsquo;s estimated 1.5 million cases of malaria each year are caused by the Plasmodium falciparum parasite, the others are caused by Plasmodium vivax .&lt;br /&gt;&lt;br /&gt;&amp;ldquo;This new drug is intended for the treatment of uncomplicated falciparum malaria &amp;mdash; not for severe malaria (also known as malignant malaria) which requires different treatment strategies,&amp;rdquo; said Neena Valecha, a senior scientist at the National Institute of Malaria Research, New Delhi, who was involved in assessing the clinical trials of the drug in India.&lt;br /&gt;&lt;br /&gt;Malaria patients who also have severe anaemia or severe jaundice or have developed cerebral malaria are not classified as having uncomplicated malaria, Valecha said.&amp;ldquo;Early treatment reduces the risk of complicated malaria.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;The number of deaths caused by malaria in India remains in dispute with some researchers challenging the government&amp;rsquo;s claim that about 1000 people die from malaria each year. The Union health minister Ghulam Nabi Azad, who was the chief guest at today&amp;rsquo;s launch, said the Indian Council of Medical Research is assessing a revised estimate of about 35,000 deaths per year made by a panel of experts set up by the health ministry.&lt;br /&gt;&lt;br /&gt;The standard therapy for uncomplicated falciparum malaria involves artemisinin-based drugs which are substances derived from plants whose availability hinges on crop output. However, arterolane production can be scaled up whenever required because of its synthetic origin.&lt;br /&gt;&lt;br /&gt;Ranbaxy began to pursue research on arterolane jointly with the international agency Medicines for Malaria Venture in 2003, and continued to pursue its development even after MMV withdrew financial support in early 2007. The company then turned to the DST for the series of crucial clinical trials that led to approval by drug regulators.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;We&amp;rsquo;re hoping that the government considers this drug for inclusion into the national malaria treatment programme,&amp;rdquo; Arun Sawhney, the chief executive officer of Ranbaxy, told reporters at the launch today.&lt;br /&gt;&lt;br /&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 14617,
	&#039;title&#039; =&gt; &#039;Malaria drug, made in India&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world&#039;s latest drug against malaria, an alternative to standard anti-malarial therapy.&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s Ranbaxy Laboratories today launched the new drug for the treatment of uncomplicated malaria caused by the Plasmodium falciparum parasite, after nine years of research which was partly supported by the Indian government.&lt;br /&gt;
&lt;br /&gt;
Clinical trials in India, Tanzania, and Thailand have suggested that the drug yields a cure rate of over 95 per cent and could serve as an alternative to existing anti-malarial therapy based on the compound called artemisinin derived from plants. Senior Ranbaxy officials announced today that the drug would be made available in India at Rs 130 for three tablets, and treatment would involve taking a single tablet for three days.&lt;br /&gt;
&lt;br /&gt;
The drug is a combination of two molecules &amp;mdash; arterolane, discovered and patented several years ago by Professor Jonathan Vennestrom, a medicinal chemistry expert at the University of Nebraska Medical Centre in the US &amp;mdash; and piperaquine, an anti-malarial known since the 1960s.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;Arterolane is a short-acting anti-malarial molecule and piperaquine is a long-acting molecule. We&amp;rsquo;ve combined the two to create a new combination therapy exactly on lines recommended by the World Health Organisation,&amp;quot; said Sudershan Arora, head of research at Ranbaxy.&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s department of science and technology (DST) contributed about Rs 5 crore to the research that involved, among other objectives, changing the salt structure of arterolane. &amp;ldquo;We changed it from a tosylate salt to a maleate salt, increasing its solubility and thus its availability in the body,&amp;rdquo; Arora said.&lt;br /&gt;
&lt;br /&gt;
Public health specialists estimate that about half of India&amp;rsquo;s estimated 1.5 million cases of malaria each year are caused by the Plasmodium falciparum parasite, the others are caused by Plasmodium vivax .&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;This new drug is intended for the treatment of uncomplicated falciparum malaria &amp;mdash; not for severe malaria (also known as malignant malaria) which requires different treatment strategies,&amp;rdquo; said Neena Valecha, a senior scientist at the National Institute of Malaria Research, New Delhi, who was involved in assessing the clinical trials of the drug in India.&lt;br /&gt;
&lt;br /&gt;
Malaria patients who also have severe anaemia or severe jaundice or have developed cerebral malaria are not classified as having uncomplicated malaria, Valecha said.&amp;ldquo;Early treatment reduces the risk of complicated malaria.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
The number of deaths caused by malaria in India remains in dispute with some researchers challenging the government&amp;rsquo;s claim that about 1000 people die from malaria each year. The Union health minister Ghulam Nabi Azad, who was the chief guest at today&amp;rsquo;s launch, said the Indian Council of Medical Research is assessing a revised estimate of about 35,000 deaths per year made by a panel of experts set up by the health ministry.&lt;br /&gt;
&lt;br /&gt;
The standard therapy for uncomplicated falciparum malaria involves artemisinin-based drugs which are substances derived from plants whose availability hinges on crop output. However, arterolane production can be scaled up whenever required because of its synthetic origin.&lt;br /&gt;
&lt;br /&gt;
Ranbaxy began to pursue research on arterolane jointly with the international agency Medicines for Malaria Venture in 2003, and continued to pursue its development even after MMV withdrew financial support in early 2007. The company then turned to the DST for the series of crucial clinical trials that led to approval by drug regulators.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;We&amp;rsquo;re hoping that the government considers this drug for inclusion into the national malaria treatment programme,&amp;rdquo; Arun Sawhney, the chief executive officer of Ranbaxy, told reporters at the launch today.&lt;br /&gt;
&lt;br /&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 26 April, 2012, http://www.telegraphindia.com/1120426/jsp/nation/story_15420477.jsp#.T5jZtVL5nYQ&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;malaria-drug-made-in-india-14741&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 14741,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 14617
$metaTitle = &#039;LATEST NEWS UPDATES | Malaria drug, made in India&#039;
$metaKeywords = &#039;malaria,Health&#039;
$metaDesc = &#039;
-The Telegraph

An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world&#039;s latest drug against malaria, an alternative to standard anti-malarial therapy.

India&amp;rsquo;s Ranbaxy Laboratories today launched the new drug for...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world&#039;s latest drug against malaria, an alternative to standard anti-malarial therapy.&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s Ranbaxy Laboratories today launched the new drug for the treatment of uncomplicated malaria caused by the Plasmodium falciparum parasite, after nine years of research which was partly supported by the Indian government.&lt;br /&gt;&lt;br /&gt;Clinical trials in India, Tanzania, and Thailand have suggested that the drug yields a cure rate of over 95 per cent and could serve as an alternative to existing anti-malarial therapy based on the compound called artemisinin derived from plants. Senior Ranbaxy officials announced today that the drug would be made available in India at Rs 130 for three tablets, and treatment would involve taking a single tablet for three days.&lt;br /&gt;&lt;br /&gt;The drug is a combination of two molecules &amp;mdash; arterolane, discovered and patented several years ago by Professor Jonathan Vennestrom, a medicinal chemistry expert at the University of Nebraska Medical Centre in the US &amp;mdash; and piperaquine, an anti-malarial known since the 1960s.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;Arterolane is a short-acting anti-malarial molecule and piperaquine is a long-acting molecule. We&amp;rsquo;ve combined the two to create a new combination therapy exactly on lines recommended by the World Health Organisation,&amp;quot; said Sudershan Arora, head of research at Ranbaxy.&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s department of science and technology (DST) contributed about Rs 5 crore to the research that involved, among other objectives, changing the salt structure of arterolane. &amp;ldquo;We changed it from a tosylate salt to a maleate salt, increasing its solubility and thus its availability in the body,&amp;rdquo; Arora said.&lt;br /&gt;&lt;br /&gt;Public health specialists estimate that about half of India&amp;rsquo;s estimated 1.5 million cases of malaria each year are caused by the Plasmodium falciparum parasite, the others are caused by Plasmodium vivax .&lt;br /&gt;&lt;br /&gt;&amp;ldquo;This new drug is intended for the treatment of uncomplicated falciparum malaria &amp;mdash; not for severe malaria (also known as malignant malaria) which requires different treatment strategies,&amp;rdquo; said Neena Valecha, a senior scientist at the National Institute of Malaria Research, New Delhi, who was involved in assessing the clinical trials of the drug in India.&lt;br /&gt;&lt;br /&gt;Malaria patients who also have severe anaemia or severe jaundice or have developed cerebral malaria are not classified as having uncomplicated malaria, Valecha said.&amp;ldquo;Early treatment reduces the risk of complicated malaria.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;The number of deaths caused by malaria in India remains in dispute with some researchers challenging the government&amp;rsquo;s claim that about 1000 people die from malaria each year. The Union health minister Ghulam Nabi Azad, who was the chief guest at today&amp;rsquo;s launch, said the Indian Council of Medical Research is assessing a revised estimate of about 35,000 deaths per year made by a panel of experts set up by the health ministry.&lt;br /&gt;&lt;br /&gt;The standard therapy for uncomplicated falciparum malaria involves artemisinin-based drugs which are substances derived from plants whose availability hinges on crop output. However, arterolane production can be scaled up whenever required because of its synthetic origin.&lt;br /&gt;&lt;br /&gt;Ranbaxy began to pursue research on arterolane jointly with the international agency Medicines for Malaria Venture in 2003, and continued to pursue its development even after MMV withdrew financial support in early 2007. The company then turned to the DST for the series of crucial clinical trials that led to approval by drug regulators.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;We&amp;rsquo;re hoping that the government considers this drug for inclusion into the national malaria treatment programme,&amp;rdquo; Arun Sawhney, the chief executive officer of Ranbaxy, told reporters at the launch today.&lt;br /&gt;&lt;br /&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/malaria-drug-made-in-india-14741.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Malaria drug, made in India | Im4change.org</title>
    <meta name="description" content="
-The Telegraph

An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world's latest drug against malaria, an alternative to standard anti-malarial therapy.

India&rsquo;s Ranbaxy Laboratories today launched the new drug for..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Malaria drug, made in India</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Telegraph<br /><br />An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world's latest drug against malaria, an alternative to standard anti-malarial therapy.<br /><br />India&rsquo;s Ranbaxy Laboratories today launched the new drug for the treatment of uncomplicated malaria caused by the Plasmodium falciparum parasite, after nine years of research which was partly supported by the Indian government.<br /><br />Clinical trials in India, Tanzania, and Thailand have suggested that the drug yields a cure rate of over 95 per cent and could serve as an alternative to existing anti-malarial therapy based on the compound called artemisinin derived from plants. Senior Ranbaxy officials announced today that the drug would be made available in India at Rs 130 for three tablets, and treatment would involve taking a single tablet for three days.<br /><br />The drug is a combination of two molecules &mdash; arterolane, discovered and patented several years ago by Professor Jonathan Vennestrom, a medicinal chemistry expert at the University of Nebraska Medical Centre in the US &mdash; and piperaquine, an anti-malarial known since the 1960s.<br /><br />&ldquo;Arterolane is a short-acting anti-malarial molecule and piperaquine is a long-acting molecule. We&rsquo;ve combined the two to create a new combination therapy exactly on lines recommended by the World Health Organisation,&quot; said Sudershan Arora, head of research at Ranbaxy.<br /><br />India&rsquo;s department of science and technology (DST) contributed about Rs 5 crore to the research that involved, among other objectives, changing the salt structure of arterolane. &ldquo;We changed it from a tosylate salt to a maleate salt, increasing its solubility and thus its availability in the body,&rdquo; Arora said.<br /><br />Public health specialists estimate that about half of India&rsquo;s estimated 1.5 million cases of malaria each year are caused by the Plasmodium falciparum parasite, the others are caused by Plasmodium vivax .<br /><br />&ldquo;This new drug is intended for the treatment of uncomplicated falciparum malaria &mdash; not for severe malaria (also known as malignant malaria) which requires different treatment strategies,&rdquo; said Neena Valecha, a senior scientist at the National Institute of Malaria Research, New Delhi, who was involved in assessing the clinical trials of the drug in India.<br /><br />Malaria patients who also have severe anaemia or severe jaundice or have developed cerebral malaria are not classified as having uncomplicated malaria, Valecha said.&ldquo;Early treatment reduces the risk of complicated malaria.&rdquo;<br /><br />The number of deaths caused by malaria in India remains in dispute with some researchers challenging the government&rsquo;s claim that about 1000 people die from malaria each year. The Union health minister Ghulam Nabi Azad, who was the chief guest at today&rsquo;s launch, said the Indian Council of Medical Research is assessing a revised estimate of about 35,000 deaths per year made by a panel of experts set up by the health ministry.<br /><br />The standard therapy for uncomplicated falciparum malaria involves artemisinin-based drugs which are substances derived from plants whose availability hinges on crop output. However, arterolane production can be scaled up whenever required because of its synthetic origin.<br /><br />Ranbaxy began to pursue research on arterolane jointly with the international agency Medicines for Malaria Venture in 2003, and continued to pursue its development even after MMV withdrew financial support in early 2007. The company then turned to the DST for the series of crucial clinical trials that led to approval by drug regulators.<br /><br />&ldquo;We&rsquo;re hoping that the government considers this drug for inclusion into the national malaria treatment programme,&rdquo; Arun Sawhney, the chief executive officer of Ranbaxy, told reporters at the launch today.<br /><br /></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 14617,
		'title' => 'Malaria drug, made in India',
		'subheading' => '',
		'description' => '<div align="justify">
-The Telegraph<br />
<br />
An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world's latest drug against malaria, an alternative to standard anti-malarial therapy.<br />
<br />
India&rsquo;s Ranbaxy Laboratories today launched the new drug for the treatment of uncomplicated malaria caused by the Plasmodium falciparum parasite, after nine years of research which was partly supported by the Indian government.<br />
<br />
Clinical trials in India, Tanzania, and Thailand have suggested that the drug yields a cure rate of over 95 per cent and could serve as an alternative to existing anti-malarial therapy based on the compound called artemisinin derived from plants. Senior Ranbaxy officials announced today that the drug would be made available in India at Rs 130 for three tablets, and treatment would involve taking a single tablet for three days.<br />
<br />
The drug is a combination of two molecules &mdash; arterolane, discovered and patented several years ago by Professor Jonathan Vennestrom, a medicinal chemistry expert at the University of Nebraska Medical Centre in the US &mdash; and piperaquine, an anti-malarial known since the 1960s.<br />
<br />
&ldquo;Arterolane is a short-acting anti-malarial molecule and piperaquine is a long-acting molecule. We&rsquo;ve combined the two to create a new combination therapy exactly on lines recommended by the World Health Organisation,&quot; said Sudershan Arora, head of research at Ranbaxy.<br />
<br />
India&rsquo;s department of science and technology (DST) contributed about Rs 5 crore to the research that involved, among other objectives, changing the salt structure of arterolane. &ldquo;We changed it from a tosylate salt to a maleate salt, increasing its solubility and thus its availability in the body,&rdquo; Arora said.<br />
<br />
Public health specialists estimate that about half of India&rsquo;s estimated 1.5 million cases of malaria each year are caused by the Plasmodium falciparum parasite, the others are caused by Plasmodium vivax .<br />
<br />
&ldquo;This new drug is intended for the treatment of uncomplicated falciparum malaria &mdash; not for severe malaria (also known as malignant malaria) which requires different treatment strategies,&rdquo; said Neena Valecha, a senior scientist at the National Institute of Malaria Research, New Delhi, who was involved in assessing the clinical trials of the drug in India.<br />
<br />
Malaria patients who also have severe anaemia or severe jaundice or have developed cerebral malaria are not classified as having uncomplicated malaria, Valecha said.&ldquo;Early treatment reduces the risk of complicated malaria.&rdquo;<br />
<br />
The number of deaths caused by malaria in India remains in dispute with some researchers challenging the government&rsquo;s claim that about 1000 people die from malaria each year. The Union health minister Ghulam Nabi Azad, who was the chief guest at today&rsquo;s launch, said the Indian Council of Medical Research is assessing a revised estimate of about 35,000 deaths per year made by a panel of experts set up by the health ministry.<br />
<br />
The standard therapy for uncomplicated falciparum malaria involves artemisinin-based drugs which are substances derived from plants whose availability hinges on crop output. However, arterolane production can be scaled up whenever required because of its synthetic origin.<br />
<br />
Ranbaxy began to pursue research on arterolane jointly with the international agency Medicines for Malaria Venture in 2003, and continued to pursue its development even after MMV withdrew financial support in early 2007. The company then turned to the DST for the series of crucial clinical trials that led to approval by drug regulators.<br />
<br />
&ldquo;We&rsquo;re hoping that the government considers this drug for inclusion into the national malaria treatment programme,&rdquo; Arun Sawhney, the chief executive officer of Ranbaxy, told reporters at the launch today.<br />
<br />
</div>',
		'credit_writer' => 'The Telegraph, 26 April, 2012, http://www.telegraphindia.com/1120426/jsp/nation/story_15420477.jsp#.T5jZtVL5nYQ',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'malaria-drug-made-in-india-14741',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 14741,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 14617,
	'metaTitle' => 'LATEST NEWS UPDATES | Malaria drug, made in India',
	'metaKeywords' => 'malaria,Health',
	'metaDesc' => '
-The Telegraph

An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world's latest drug against malaria, an alternative to standard anti-malarial therapy.

India&rsquo;s Ranbaxy Laboratories today launched the new drug for...',
	'disp' => '<div align="justify">-The Telegraph<br /><br />An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world's latest drug against malaria, an alternative to standard anti-malarial therapy.<br /><br />India&rsquo;s Ranbaxy Laboratories today launched the new drug for the treatment of uncomplicated malaria caused by the Plasmodium falciparum parasite, after nine years of research which was partly supported by the Indian government.<br /><br />Clinical trials in India, Tanzania, and Thailand have suggested that the drug yields a cure rate of over 95 per cent and could serve as an alternative to existing anti-malarial therapy based on the compound called artemisinin derived from plants. Senior Ranbaxy officials announced today that the drug would be made available in India at Rs 130 for three tablets, and treatment would involve taking a single tablet for three days.<br /><br />The drug is a combination of two molecules &mdash; arterolane, discovered and patented several years ago by Professor Jonathan Vennestrom, a medicinal chemistry expert at the University of Nebraska Medical Centre in the US &mdash; and piperaquine, an anti-malarial known since the 1960s.<br /><br />&ldquo;Arterolane is a short-acting anti-malarial molecule and piperaquine is a long-acting molecule. We&rsquo;ve combined the two to create a new combination therapy exactly on lines recommended by the World Health Organisation,&quot; said Sudershan Arora, head of research at Ranbaxy.<br /><br />India&rsquo;s department of science and technology (DST) contributed about Rs 5 crore to the research that involved, among other objectives, changing the salt structure of arterolane. &ldquo;We changed it from a tosylate salt to a maleate salt, increasing its solubility and thus its availability in the body,&rdquo; Arora said.<br /><br />Public health specialists estimate that about half of India&rsquo;s estimated 1.5 million cases of malaria each year are caused by the Plasmodium falciparum parasite, the others are caused by Plasmodium vivax .<br /><br />&ldquo;This new drug is intended for the treatment of uncomplicated falciparum malaria &mdash; not for severe malaria (also known as malignant malaria) which requires different treatment strategies,&rdquo; said Neena Valecha, a senior scientist at the National Institute of Malaria Research, New Delhi, who was involved in assessing the clinical trials of the drug in India.<br /><br />Malaria patients who also have severe anaemia or severe jaundice or have developed cerebral malaria are not classified as having uncomplicated malaria, Valecha said.&ldquo;Early treatment reduces the risk of complicated malaria.&rdquo;<br /><br />The number of deaths caused by malaria in India remains in dispute with some researchers challenging the government&rsquo;s claim that about 1000 people die from malaria each year. The Union health minister Ghulam Nabi Azad, who was the chief guest at today&rsquo;s launch, said the Indian Council of Medical Research is assessing a revised estimate of about 35,000 deaths per year made by a panel of experts set up by the health ministry.<br /><br />The standard therapy for uncomplicated falciparum malaria involves artemisinin-based drugs which are substances derived from plants whose availability hinges on crop output. However, arterolane production can be scaled up whenever required because of its synthetic origin.<br /><br />Ranbaxy began to pursue research on arterolane jointly with the international agency Medicines for Malaria Venture in 2003, and continued to pursue its development even after MMV withdrew financial support in early 2007. The company then turned to the DST for the series of crucial clinical trials that led to approval by drug regulators.<br /><br />&ldquo;We&rsquo;re hoping that the government considers this drug for inclusion into the national malaria treatment programme,&rdquo; Arun Sawhney, the chief executive officer of Ranbaxy, told reporters at the launch today.<br /><br /></div>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 14617,
	'title' => 'Malaria drug, made in India',
	'subheading' => '',
	'description' => '<div align="justify">
-The Telegraph<br />
<br />
An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world's latest drug against malaria, an alternative to standard anti-malarial therapy.<br />
<br />
India&rsquo;s Ranbaxy Laboratories today launched the new drug for the treatment of uncomplicated malaria caused by the Plasmodium falciparum parasite, after nine years of research which was partly supported by the Indian government.<br />
<br />
Clinical trials in India, Tanzania, and Thailand have suggested that the drug yields a cure rate of over 95 per cent and could serve as an alternative to existing anti-malarial therapy based on the compound called artemisinin derived from plants. Senior Ranbaxy officials announced today that the drug would be made available in India at Rs 130 for three tablets, and treatment would involve taking a single tablet for three days.<br />
<br />
The drug is a combination of two molecules &mdash; arterolane, discovered and patented several years ago by Professor Jonathan Vennestrom, a medicinal chemistry expert at the University of Nebraska Medical Centre in the US &mdash; and piperaquine, an anti-malarial known since the 1960s.<br />
<br />
&ldquo;Arterolane is a short-acting anti-malarial molecule and piperaquine is a long-acting molecule. We&rsquo;ve combined the two to create a new combination therapy exactly on lines recommended by the World Health Organisation,&quot; said Sudershan Arora, head of research at Ranbaxy.<br />
<br />
India&rsquo;s department of science and technology (DST) contributed about Rs 5 crore to the research that involved, among other objectives, changing the salt structure of arterolane. &ldquo;We changed it from a tosylate salt to a maleate salt, increasing its solubility and thus its availability in the body,&rdquo; Arora said.<br />
<br />
Public health specialists estimate that about half of India&rsquo;s estimated 1.5 million cases of malaria each year are caused by the Plasmodium falciparum parasite, the others are caused by Plasmodium vivax .<br />
<br />
&ldquo;This new drug is intended for the treatment of uncomplicated falciparum malaria &mdash; not for severe malaria (also known as malignant malaria) which requires different treatment strategies,&rdquo; said Neena Valecha, a senior scientist at the National Institute of Malaria Research, New Delhi, who was involved in assessing the clinical trials of the drug in India.<br />
<br />
Malaria patients who also have severe anaemia or severe jaundice or have developed cerebral malaria are not classified as having uncomplicated malaria, Valecha said.&ldquo;Early treatment reduces the risk of complicated malaria.&rdquo;<br />
<br />
The number of deaths caused by malaria in India remains in dispute with some researchers challenging the government&rsquo;s claim that about 1000 people die from malaria each year. The Union health minister Ghulam Nabi Azad, who was the chief guest at today&rsquo;s launch, said the Indian Council of Medical Research is assessing a revised estimate of about 35,000 deaths per year made by a panel of experts set up by the health ministry.<br />
<br />
The standard therapy for uncomplicated falciparum malaria involves artemisinin-based drugs which are substances derived from plants whose availability hinges on crop output. However, arterolane production can be scaled up whenever required because of its synthetic origin.<br />
<br />
Ranbaxy began to pursue research on arterolane jointly with the international agency Medicines for Malaria Venture in 2003, and continued to pursue its development even after MMV withdrew financial support in early 2007. The company then turned to the DST for the series of crucial clinical trials that led to approval by drug regulators.<br />
<br />
&ldquo;We&rsquo;re hoping that the government considers this drug for inclusion into the national malaria treatment programme,&rdquo; Arun Sawhney, the chief executive officer of Ranbaxy, told reporters at the launch today.<br />
<br />
</div>',
	'credit_writer' => 'The Telegraph, 26 April, 2012, http://www.telegraphindia.com/1120426/jsp/nation/story_15420477.jsp#.T5jZtVL5nYQ',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'malaria-drug-made-in-india-14741',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 14741,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 14617
$metaTitle = 'LATEST NEWS UPDATES | Malaria drug, made in India'
$metaKeywords = 'malaria,Health'
$metaDesc = '
-The Telegraph

An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world's latest drug against malaria, an alternative to standard anti-malarial therapy.

India&rsquo;s Ranbaxy Laboratories today launched the new drug for...'
$disp = '<div align="justify">-The Telegraph<br /><br />An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world's latest drug against malaria, an alternative to standard anti-malarial therapy.<br /><br />India&rsquo;s Ranbaxy Laboratories today launched the new drug for the treatment of uncomplicated malaria caused by the Plasmodium falciparum parasite, after nine years of research which was partly supported by the Indian government.<br /><br />Clinical trials in India, Tanzania, and Thailand have suggested that the drug yields a cure rate of over 95 per cent and could serve as an alternative to existing anti-malarial therapy based on the compound called artemisinin derived from plants. Senior Ranbaxy officials announced today that the drug would be made available in India at Rs 130 for three tablets, and treatment would involve taking a single tablet for three days.<br /><br />The drug is a combination of two molecules &mdash; arterolane, discovered and patented several years ago by Professor Jonathan Vennestrom, a medicinal chemistry expert at the University of Nebraska Medical Centre in the US &mdash; and piperaquine, an anti-malarial known since the 1960s.<br /><br />&ldquo;Arterolane is a short-acting anti-malarial molecule and piperaquine is a long-acting molecule. We&rsquo;ve combined the two to create a new combination therapy exactly on lines recommended by the World Health Organisation,&quot; said Sudershan Arora, head of research at Ranbaxy.<br /><br />India&rsquo;s department of science and technology (DST) contributed about Rs 5 crore to the research that involved, among other objectives, changing the salt structure of arterolane. &ldquo;We changed it from a tosylate salt to a maleate salt, increasing its solubility and thus its availability in the body,&rdquo; Arora said.<br /><br />Public health specialists estimate that about half of India&rsquo;s estimated 1.5 million cases of malaria each year are caused by the Plasmodium falciparum parasite, the others are caused by Plasmodium vivax .<br /><br />&ldquo;This new drug is intended for the treatment of uncomplicated falciparum malaria &mdash; not for severe malaria (also known as malignant malaria) which requires different treatment strategies,&rdquo; said Neena Valecha, a senior scientist at the National Institute of Malaria Research, New Delhi, who was involved in assessing the clinical trials of the drug in India.<br /><br />Malaria patients who also have severe anaemia or severe jaundice or have developed cerebral malaria are not classified as having uncomplicated malaria, Valecha said.&ldquo;Early treatment reduces the risk of complicated malaria.&rdquo;<br /><br />The number of deaths caused by malaria in India remains in dispute with some researchers challenging the government&rsquo;s claim that about 1000 people die from malaria each year. The Union health minister Ghulam Nabi Azad, who was the chief guest at today&rsquo;s launch, said the Indian Council of Medical Research is assessing a revised estimate of about 35,000 deaths per year made by a panel of experts set up by the health ministry.<br /><br />The standard therapy for uncomplicated falciparum malaria involves artemisinin-based drugs which are substances derived from plants whose availability hinges on crop output. However, arterolane production can be scaled up whenever required because of its synthetic origin.<br /><br />Ranbaxy began to pursue research on arterolane jointly with the international agency Medicines for Malaria Venture in 2003, and continued to pursue its development even after MMV withdrew financial support in early 2007. The company then turned to the DST for the series of crucial clinical trials that led to approval by drug regulators.<br /><br />&ldquo;We&rsquo;re hoping that the government considers this drug for inclusion into the national malaria treatment programme,&rdquo; Arun Sawhney, the chief executive officer of Ranbaxy, told reporters at the launch today.<br /><br /></div>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Malaria drug, made in India

-The Telegraph An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world's latest drug against malaria, an alternative to standard anti-malarial therapy. India’s Ranbaxy Laboratories today launched the new drug for the treatment of uncomplicated malaria caused by the Plasmodium falciparum parasite, after nine years of research which was partly supported by the Indian government. Clinical trials in India, Tanzania, and Thailand have suggested that the drug yields a cure rate of over 95 per cent and could serve as an alternative to existing anti-malarial therapy based on the compound called artemisinin derived from plants. Senior Ranbaxy officials announced today that the drug would be made available in India at Rs 130 for three tablets, and treatment would involve taking a single tablet for three days. The drug is a combination of two molecules — arterolane, discovered and patented several years ago by Professor Jonathan Vennestrom, a medicinal chemistry expert at the University of Nebraska Medical Centre in the US — and piperaquine, an anti-malarial known since the 1960s. “Arterolane is a short-acting anti-malarial molecule and piperaquine is a long-acting molecule. We’ve combined the two to create a new combination therapy exactly on lines recommended by the World Health Organisation," said Sudershan Arora, head of research at Ranbaxy. India’s department of science and technology (DST) contributed about Rs 5 crore to the research that involved, among other objectives, changing the salt structure of arterolane. “We changed it from a tosylate salt to a maleate salt, increasing its solubility and thus its availability in the body,” Arora said. Public health specialists estimate that about half of India’s estimated 1.5 million cases of malaria each year are caused by the Plasmodium falciparum parasite, the others are caused by Plasmodium vivax . “This new drug is intended for the treatment of uncomplicated falciparum malaria — not for severe malaria (also known as malignant malaria) which requires different treatment strategies,” said Neena Valecha, a senior scientist at the National Institute of Malaria Research, New Delhi, who was involved in assessing the clinical trials of the drug in India. Malaria patients who also have severe anaemia or severe jaundice or have developed cerebral malaria are not classified as having uncomplicated malaria, Valecha said.“Early treatment reduces the risk of complicated malaria.” The number of deaths caused by malaria in India remains in dispute with some researchers challenging the government’s claim that about 1000 people die from malaria each year. The Union health minister Ghulam Nabi Azad, who was the chief guest at today’s launch, said the Indian Council of Medical Research is assessing a revised estimate of about 35,000 deaths per year made by a panel of experts set up by the health ministry. The standard therapy for uncomplicated falciparum malaria involves artemisinin-based drugs which are substances derived from plants whose availability hinges on crop output. However, arterolane production can be scaled up whenever required because of its synthetic origin. Ranbaxy began to pursue research on arterolane jointly with the international agency Medicines for Malaria Venture in 2003, and continued to pursue its development even after MMV withdrew financial support in early 2007. The company then turned to the DST for the series of crucial clinical trials that led to approval by drug regulators. “We’re hoping that the government considers this drug for inclusion into the national malaria treatment programme,” Arun Sawhney, the chief executive officer of Ranbaxy, told reporters at the launch today.